IMPACT OF RAKTABASTI ON SEVERE ANEMIA AND ON REDUCTION OF SERUM CREATININE LEVEL IN CKD STAGE 5: A CLINICAL TRIAL
Dr. Sarita Gaikwad*
A clinical trial was undertaken in Ayurvedic Research Department of Sassoon hospital, Pune to evaluate the effect of Raktabasti in 39 patients with severe Anaemia due to End Stage Renal Disease (ESRD).The average age of study subjects was found to be 44.74 years. 60 ml. of blood of a previously screened donor (a close relative) was given to the patient per rectally. The same procedure was repeated after 48 hours. The Haemoglobin rise after two Raktabasti given 48 hours apart was studied after next 48 hours. Raktabasti of total 120 ml blood has showed statistically significant rise in the Haemoglobin level on an average by 1.65 gm/ dL. Further we found inverse/ negative correlation between Haemoglobin and Creatinine that indicated that as Haemoglobin rises, there is reduction in Creatinine value. The mean Creatinine level of the study subjects was 8.63 mg/dL ±3.49 before Raktabasti was administered. The Creatinine value after 48 hours of Raktabasti was noted to be 7.35±2.92 mg/dL- a net reduction of 14.83% which was statistically highly significant. The present study proved that Raktabasti is simple, safe and economical method of treating severe Anaemia in CKD-5 patients with its added advantage of reducing Serum Creatinine level.
Keywords: ESRD, CKD stage 5, Anemia, Ayurved, Raktabasti, Creatinine level.
[Full Text Article]